1-3 of 3
Dennis Benjamin, PhD
Close
Sort by
Journal Articles

SGN-CD123A, a Pyrrolobenzodiazepine Dimer Linked Anti-CD123 Antibody Drug Conjugate, Demonstrates Effective Anti-Leukemic Activity in Multiple Preclinical Models of AML

May S.K. Sutherland, PhD, Changpu Yu, Roland B. Walter, MD PhD, Lori Westendorf, John Valliere-Douglass, PhD, Lucy Pan, PhD, Django Sussman, PhD, Martha Anderson, Weiping Zeng, Ivan Stone, Kerry Klussman, Michelle Ulrich, Mechthild Jonas, PhD, Peter Senter, PhD, Jonathan G. Drachman, MD, Dennis Benjamin, PhD
Journal: Blood
Blood (2015) 126 (23): 330.
https://doi.org/10.1182/blood.V126.23.330.330
Published: 2015
Journal Articles

SGN-CD33A in Combination with Hypomethylating Agents Is Highly Efficacious in Preclinical Models of AML

May S.K. Sutherland, PhD, Changpu Yu, Christine O'Day, PhD, Steve Alley, PhD, Martha Anderson, Kim Emmerton, Weipeng Zeng, Megan M. O'Meara, MD, Eric J. Feldman, MD, Dana A. Kennedy, Maureen C. Ryan, PhD, Dennis Benjamin, PhD
Journal: Blood
Blood (2015) 126 (23): 3785.
https://doi.org/10.1182/blood.V126.23.3785.3785
Published: 2015
Journal Articles

SGN-CD19B, a Pyrrolobenzodiazepine (PBD)-Based Anti-CD19 Drug Conjugate, Demonstrates Potent Preclinical Activity Against B-Cell Malignancies

Maureen C. Ryan, PhD, Brian Schimpf, Martha Anderson, Weiping Zeng, Kim Emmerton, Jamie Miyamoto, Heather Kostner, Changpu Yu, Heather Van Epps, PhD, Laurie Tatalick, DVM, PhD DACVP, Dennis Benjamin, PhD
Journal: Blood
Blood (2015) 126 (23): 594.
https://doi.org/10.1182/blood.V126.23.594.594
Published: 2015